Cytognos products now available online! We are excited to announce that Cytognos products are now also available through the BDB online store. Explore the integrated BD-Cytognos portfolio, enhance your diagnostic and research capabilities, and the journey from diagnosis to monitoring and disease follow-up. Visit BDB website to learn more about the extensive range of cutting-edge reagents designed to elevate your clinical practice: Single-color antibodies Multi-color cocktails and kits [...]

Customers in selected countries now purchase Cytognos references directly from BD As of November 9, 2022, customers in the following countries will purchase Cytognos products directly through BD: Austria, Belgium, France, Germany, Ireland, Italy, Luxembourg, Switzerland, the Netherlands and the UK. You can check your current supplier here.

BD Expands Flow Cytometry Portfolio with Acquisition of Cytognos As the understanding and treatment of cancer evolves and improves, the importance of monitoring post-remission cancer survivors has become paramount to improving patient outcomes. Monitoring for minimal residual disease, or MRD, lab managers and physicians can detect low levels of cancer cells following treatment that can signal cancer recurrence. This is a key element of the patient care continuum that [...]

Cytognos would like to announce the Infinicyt™ CE-IVD Edition Infinicyt™ is a well established software in the field of clinical flow cytometry. It is recognized for being an agile software that incorporates state-of-the-art technology with the aim of facilitating multi-parametric analyses, that are becoming more and more complete and complex. With the release of Infinicyt™ 2.0.5, the RUO and the CE-IVD version under the European Directive 98/79/EC (IVDD) will [...]

The Josep Carreras Research Institute and Cytognos S.L. develop a kit to determine the prognosis of patients diagnosed with Acute Myeloid Leukaemia The Joint Cytometry Unit, formed by the Josep Carreras Leukemia Research Institute and the company Cytognos S.L., has developed a new commercial reagent that helps determine the prognosis of patients with Acute Myeloid Leukemia at the time of diagnosis. Acute Myeloid Leukemia (AML) is a very aggressive [...]